Prohibitionist group Smart Approaches to Marijuana Executive Vice President Luke Niforatos filed a PAC with the FEC that takes aim at politicians who have advocated for cannabis reform, including Rep. Nancy Mace.
Protect Our Kids; Adobe Stock
New PAC Backed by SAM Executive Launches Campaign to Unseat Rep. Nancy Mace
Protect Our Kids was filed by Smart Approaches to Marijuana executive Luke Niforatos and will target cannabis reform advocates.
After introducing a bill that aims to end federal cannabis prohibition, U.S. Rep. Nancy Mace, R-S.C., is now the target of a new political action committee (PAC) backed by a notorious prohibitionist group’s executive.
Mace’s States Reform Act (SRA) offers a path to reform that includes a 3% federal cannabis excise tax and provides state governments the power to regulate cannabis products through the health-and-safety oversights of their choosing, while authorizing the Alcohol and Tobacco Tax and Trade Bureau (TTB) to oversee cannabis products in interstate commerce.
Although Mace’s proposed legislation is one of three high-profile bills aimed at broad federal cannabis reform introduced this Congress, it was a little too ambitious for a PAC called Protect Our Kids, which prohibitionist group Smart Approaches to Marijuana (SAM) Executive Vice President Luke Niforatos filed with the Federal Election Commission (FEC) in January.
The PAC announced March 28 it would be running digital advertising “educating Republican primary voters on Rep. Mace’s destructive policy positions,” The Post and Courierreported.
While Protect Our Kids will operate separately from SAM, the ties remain.
Formed in 2013, after Colorado and Washington voters approved adult-use legalization measures in the November 2012 election, SAM was co-founded by Kevin Sabet, a former three-time adviser for the White House’s Office of National Drug Control Policy. The organization aims to create policies that decrease cannabis use.
Tax documents filed by SAM in 2019 show the group has annual revenues in the millions.
Niforatos joined SAM in 2017 as a chief of staff and senior policy adviser, before getting promoted to executive VP in 2020.
Niforatos launched the Protect Our Kids PAC with a group of several parents who are “tired of lax drug policies that harm our kids,” according to the committee’s website.
“Thrilled to announce a project I’ve been working on quietly the past year,” Niforatos said on social media March 29. “Through partnership with more than a dozen parents and counting across the nation, I have launched a nonpartisan national super PAC. We are getting active this cycle to encourage sound drug policy.”
Protect Our Kids will funnel tens of thousands of dollars into South Carolina’s 1st Congressional District in an effort to unseat Mace, Niforatos told The Post and Courier. The PAC will also target at least six other federal and state-level races this year behind funding that exceeds $1 million, Niforatos said.
Protect Our Kids has not yet reported any donations or filed a campaign finance disclosure with the FEC, the news outlet reported.
Aubree Adams, a member of the PAC who said her son is addicted to cannabis, said on social media, “At a time where crime and drug use are at epidemic levels in this country, Nancy Mace has decided to become the Republican face of marijuana legalization.”
Other members of the committee made similar claims about their families having been negatively impacted by youth cannabis use.
Laura Stack said, “I lost my son to high-potency marijuana. That’s why I am fighting for smart drug policies.”
Sally Schindel said, “My son died by suicide and said marijuana caused it in his note. I don’t want industries making money off addicting our kids.”
Corinne Gasper said, “I lost my daughter to a stoned driver. That’s why I am asking parents everywhere to stand up and do something about the drug crisis in our country.”
While the PAC is targeting certain pro-reform politicians, it is putting its support behind state Rep. Lauren Davis, D-Wash.; state Rep. Kimberly Moser, R-Ky.; former federal prosecutor Mike Stuart, a Republican running for a state Senate seat in West Virginia; and state Rep. Yadira Caraveo, D-Colo., who is a candidate for the U.S. House.
At a time when proponents of cannabis legalization tout the plant’s medical benefits, from treating conditions like post-traumatic stress disorder (PTSD), multiple sclerosis, nausea, chronic pain and other health issues, the percentage of Americans who support policy reform remains at a record high.
According to a November 2021 Gallop Poll, 68% of Americans support full legalization of cannabis. Furthermore, 91% of U.S. adults support federal legalization of medical cannabis, according to an April 2021 survey conducted by the Pew Research Center.
Recent reform efforts, including 37 states that have legalized the commercial production and sale of medical cannabis without low-THC restrictions, as well as 18 states that have legalized adult-use, also come at a time when an estimated 40,000 people remain incarcerated for cannabis offenses, according to a 2020 Forbes report.
According to a 2020 Pew Research Center report, 40% of U.S. drug arrests in 2018 were for cannabis-related offenses.
Lulla | Adobe Stock
South Carolina Medical Cannabis Bill Scheduled for First House Hearing After Senate Approval
The SC Compassionate Care Act, which cleared the Senate last month, will be considered by the House Medical, Military, Public and Municipal Affairs subcommittee March 31.
The fate of South Carolina’s medical cannabis legalization measure is in the hands of a House panel this week after the bill passed the Senate last month.
The six-member Medical, Military, Public and Municipal Affairs subcommittee will hold a hearing on S. 150, the SC Compassionate Care Act, on March 31, according to The State.
The legislation, sponsored by South Carolina Sen. Tom Davis, R-Beaufort, outlines 13 qualifying conditions, including cancer, multiple sclerosis, post-traumatic stress disorder, chronic medical conditions causing serious muscle spasms, and any chronic or debilitating condition for which an opioid is prescribed.
The bill would allow patients to access a two-week supply of medical cannabis in the form of oils, vaporizers, salves, topicals and patches.
The legislation would levy a 6% sales tax on medical cannabis products, and would grant South Carolina’s cities and counties the power to opt out of hosting the industry within their jurisdictions.
Davis has been advocating for medical cannabis reform for years, and while a similar proposal stalled in the Senate last year, this year’s legislation cleared that chamber Feb. 9 in a 28-15 vote.
Rep. Leon Howard, D-Richland, who chairs the House Medical, Military, Public and Municipal Affairs subcommittee, told The State that the SC Compassionate Care Act will likely receive the panel’s approval and advance to the full House for debate.
Rep. Joe Bustos, R-Charleston, the only Republican lawmaker on the subcommittee, told the news outlet that while he has questions about the bill’s implementation, “it deserves a fair hearing” if medical cannabis can help reduce patients’ pain.
If the SC Compassionate Care Act advances out of committee, the House will have less than two months to consider the bill before this year’s legislative session wraps up in May, The State reported.
South Carolina Gov. Henry McMaster has not yet indicated whether he plans to sign the legislation or veto it if it should clear the Legislature this year, according to the news outlet.
10 Years In The Making: Q&A With G Pen CEO Chris Folkerts
As Grenco Science, the company behind the G Pen, celebrates its 10-year anniversary, founder and CEO Chris Folkerts reflects on his journey through cannabis, the California market, and more.
Grenco Science, the company behind the G Pen, is celebrating its 10-year anniversary this year since the company's founding in 2012.
Not only is Grenco Science celebrating its decade milestone, but company founder and CEO Chris Folkerts also recently celebrated his 40th birthday earlier this month. As he reaches new milestones both professionally and personally, Folkerts sat down with Cannabis Business Times to reflect on his company’s history, his career in cannabis, the California market, and more.
Zach Mentz: How did you get your start in this industry and how did you end up here as founder and CEO of Grenco Science?
Chris Folkerts: Not only did my company turn 10 [in February], but I turned 40 [in March], so it's kind of an interesting moment … I think it's a nice intersection of where I expected I would be in life and where I thought the company (Grenco Science) would be.
There was this ‘it’ moment in a dispensary called LA Confidential in Los Angeles that was very known as an epicenter for a lot of the culture and lifestyle that happened. They had a hash bar, and they did jazz and comedy nights, things like that, and so this became very much of a hangout for me and a lot of people. The (California) market was still medicinal, shops were plentiful, it was pretty easy to get yourself into a space and it was pretty easy to get yourself set up. That was the landscape for the industry. You had growers and you had shops and you had middlemen in between.
As I was hanging out and being there, I saw the very first product where somebody figured out how to utilize e-cig technology that was currently available. I saw somebody that figured it out, a guy out of the Bay Area with a product called the “Vape Pen,” literally. It came with little prefilled cotton cartomizer that had been filled with some sort of a tincture which has some sort of either an ethanol or a glycerin mix and could be vaporized. So I screwed that in, I hit the device, vapor came out, and there was an ever-so-faint taste of cannabis. And I thought that was a lightbulb going off over my head.
I was like, “This is the moment, I want to sell these things.” This is the digitization of cannabis, as I always like to call it, and I knew this is something that I could sell to people. I've always been involved in the (cannabis) industry one way or the other, regulated or not. And so that was the moment for me saying, “Okay, I believe that I could sell this to people, and all of my stores that I deal with would love that.”
That was just where my mind was at initially. As I began down the journey of trying to find these products through my attorney [and] everything else, I ultimately realized the product did not exist. Even that group Vape Pen that did it, it was really available in minimal quantities. I could buy four or eight of them at a time. There was nothing at scale. I was buying low quantities of these vape pens that were probably pretty expensive at the time, then taking them and then refilling them, so that was kind of how it started.
When I figured out that the products did not exist, I went through the process of locating groups that could assist with that [and] went through a lot of trials and tribulations with those group. After about a year or a year-and-a-half of either selling other people's products … I ultimately landed into the conclusion that my particular skill set, which was relationships with both the dispensaries and the producers, put me in a unique position … my rolodex was and has always been my biggest asset. So I looked at the business side of this and said, “Hey, I could do this. If I did it myself, I could do it better.” So G Pen was born.
ZM: What inspired the company name Grenco Science?
CF: So Grenco Science is a company name that came from a branding agency that gave us options and logos and things like that. It doesn’t mean anything, it's not a real word, I looked it up 10 ways to Tuesday. It didn’t come up with anything SEO, so I thought, “Hey, if I could just get people to start saying it, I don't have to fight anybody for the SEO.”
And this is when it gets even better. The first product was to be named the G-O. Our branding and packaging [was] inspired by Apple and the cleanness of the logo in that it was meant to have the logo on the product, the logo on the box, and nothing else.
The first 15,000 units that we made, basically 100% of them were defective and [we] sold them all. It shows how tenacious we are, and then also the demand for the product. Once people had tried it [and] used it, [they were] like, “I don't care if it's broke, give me another one.” That just goes to show that we were onto something; if you sell 15,000 of something that's broken and people want more of it, then you know you're on the right path.
Maybe one out of five just didn't work out of the box ever. Some of them would work out of the box, but after that, maybe they didn't connect with the charger, so you got to use it for the duration of the first full charge, and then that’s it. And then your atomizer could go out so you could lose a piece. And then if somebody lost something, we only had complete sets, we hadn't ordered ancillary items.
Some call it the school of hard knocks. I call it trial by fire.
ZM: Your company, Grenco Science, is best known for the G Pen. Where did that product name and branding come from?
CF: One very key, funny story at the beginning is that those first 15,000 units that we made, not only were they defective, but they didn't have an instruction manual. So most people would call and say, “Hey, it doesn't work.” You go “press the button five times,” and they'd be like, “oh, right.” So it didn't even tell you that you needed to press it five times, and unless somebody told you, you couldn't even know. Not only did the manual not exist, but nowhere on the product or the box did it say it was called the G-O. It had the G (logo) on the pen, it had a G on the box because the Grenco Science G was going to be our brand, but each product was going to have its own SKU name.
And then people started calling it the G Pen. I was like, “Okay, so that's it. We have a letter, this is cool, the people have spoken.” The way that it came about was very serendipitous. It just kind of came into existence. We were like, “Listen, everybody calls it the G Pen, so we're calling it the G Pen. It's got a G on it and it's Grenco Science.” And we meant the branding to be about the G, we just didn’t think to call it the G Pen. It was gonna be called the G-O. What we did from there was just the first one was called G Pen, and then after that it was G Pen Micro, and everything's a G Pen then since. Grenco Science is the company, G Pen is the product.
ZM: When was that moment where you felt like boom, this is starting to work?
CF: I had connections on the distribution side of things from the smoke shop industry, which is fortunately a very well-established method of distribution. Pipes, bongs, rolling papers, things like that–it's one of the most widely distributed as far as brick and mortar goes. And not that you can't buy any of these things digitally, but when somebody goes and buys a bag and they want to stop to grab a bong or they need some papers, they're not waiting [until] the next day to get them.
So we had rapid growth. We were, by the end of our first year, probably in a couple thousand stores because of the distribution.
We're in every [legal] state. I think we're in something around 60 countries at this point, too. A lot of what we do comes from the distributors who are already established in those regions. And look, that's great. If distributors are doing their job, then they're an essential part of the company because they have years of relationships, the time, logistics worked out–all that.
ZM:What is the current state of the California market from your perspective? And how do you think it can be improved?
CF: I'm going to come to probably the first answer that everybody else is, which is taxes. When you've got people that are struggling as hard as they are right now, financially, it is difficult. And for an industry that actually is recession proof, which cannabis is, I see that people are struggling. You can’t have the kind of taxation on this product, versus having a 10% tax on alcohol that people can walk into a store, buy a handle of alcohol, andthat be something that gets them through, versus something like cannabis that's a medicine. No doctor's ever going to prescribe you to go get that handle of vodka, but there are doctors all throughout the state of California that have been [prescribing cannabis] since 1996. So why is it that I'm taxed differently because of that?
It still baffles me and a lot of other people, and I think we all agree that it all starts with taxes. … What's wrong with California's market is that (the state) is allowing the people who have laid the foundation of this industry to be robbed of their intellectual property, and they’re forcing those people to be taxed at such a ridiculous rate?
ZM: What would be your advice to new or existing operators in the cannabis industry?
CF: If anybody wants to take anything from this … partnerships are one of the most important decisions you're ever going to have to make in your life. It is very difficult to predict the future. But what you can do is understand that a lot of businesses fail, and a lot of things fail for a lot of different reasons. Not having sound operating agreements, not having your business in order, and not understanding the contract, what you're doing, what you're signing without having really good people around you to advise you can be extremely costly in a world where the lessons that I got to learn 10 years ago would kill a company dead in its tracks today. You’d never be able to survive the stuff that we were able to survive because it was different times.
I cannot emphasize enough that a partnership is filling a void, right? You're filling voids for each other. You can have duplicities, but if you create all these duplicities and you're the same person trying to do the same thing, or you have bad actors, or you have people that you haven't properly vetted and you go into a business with your heart and you act emotionally, either in the business or as an individual, be careful. Speaking strictly from experience, these are the type of situations where you're dealing with uncomfortable conversations and you're dealing with extremely complex litigations that if you're not prepared for–financially, mentally, et cetera–is something I just don't wish people to go through.
When you're making decisions upon going into partnerships with people, you should always think of it as just like saying, ‘Hey, will you marry me?’ to somebody and, in a lot of cases, [it’s] way worse than asking somebody to marry you. Because if [a business partner] says yes, now you're in business. … It’s so important for people to think about it like that. And I don't think people do. It's all gung-ho, let's start a business, we're going to be partners, we're boys now, we're best buddies forever. That is not how life works.
Katherine | Adobe Stock
Legislation Pending in Congress Could Authorize Clinical Medical Cannabis Trials for Veterans
The VA Cannabis Research Act of 2021 would require the Secretary of Veterans Affairs to conduct a series of clinical trials on the effects of cannabis on patients with chronic pain and PTSD.
Legislation on Capitol Hill would allow for research on cannabis as a treatment for veterans with chronic pain and post-traumatic stress disorder (PTSD)—if it can first pass out of committee.
Senate Bill 1467 and House Resolution 2916, known as the “VA Cannabis Research Act of 2021,” would require the Secretary of Veterans Affairs to conduct a series of clinical trials on the effects of cannabis on patients with these conditions.
The Senate version of the legislation was introduced in April 2021 by Sen. Jon Tester, D-Mont., and has not seen any movement since a June 2021 hearing by the Committee on Veterans Affairs. S.B. 1467 has picked up one cosponsor, Sen. Dan Sullivan, R-Alaska.
The House version of the legislation, also introduced in April 2021, is sponsored by Rep. Lou Correa, D-Calif., and has four co-sponsors: Reps. Peter Meijer, R-Mich.; Elaine Luria, D-Va.; Andy Kim, D-N.J.; and Suzan DelBene, D-Wash., who just recently signed on to the legislation earlier this month.
Disabled American Veterans (DAV), a nonprofit organization that, in part, helps fight for veterans’ interests on Capitol Hill, backs both bills.
“We do what we can when we find legislation that we can support to let our members know ... here is something that is potentially good for you or something you have asked for that we think is good legislation, and be sure to let your legislators know that," DAV Assistant National Legislative Director Marquis Barefield told WCPO.
Canadian Cannabis Companies Partner on Amnesty Fellowship Program
The TOQi Fellowship for Cannabis Amnesty program, supported by Cannabis Amnesty, TOQi Technologies and Aurora Cannabis, will create salaried internship opportunities for those most impacted by cannabis prohibition.
Cannabis Amnesty, a Canadian non-profit advocacy group, and TOQi Technologies have partnered to launch the TOQi Fellowship for Cannabis Amnesty program.
The fellowship program will support two salaried internship positions during the summer of 2022, with support from Aurora Cannabis. The internships were designed to create economic opportunities for those from communities most impacted by decades of cannabis prohibition.
Throughout the program, fellows will gain experience in advocacy and communications through mentorship, networking opportunities, and additional perspective on the cannabis industry and Cannabis Amnesty's mission.
"Historically, cannabis laws were unequally enforced by law enforcement in Canada, disproportionately impacting Black, Indigenous and under-resourced communities," said Annamaria Enenajor, executive director of Cannabis Amnesty. "Cannabis convictions limit economic opportunities for people from these communities, thus further entrenching systemic racism through poverty and disenfranchisement. We are grateful to TOQi and Aurora Cannabis for their leadership in supporting our efforts to dismantle these economic barriers, and look forward to welcoming more cannabis brands to our shared vision of justice and equality in the cannabis industry."
The program will run from May through August, and prospective applicants can apply here. Applications will be accepted through April 19.
"As a proudly Canadian company, Aurora values our roots in advocating for cannabis record pardons with Cannabis Amnesty," said Miguel Martin, CEO of Aurora Cannabis. "We have a responsibility to those who have been disproportionately impacted and commit to doing our part. Canadians, or anyone for that matter, shouldn't be burdened with a criminal record for a minor, non-harmful act that is no longer a crime. We deeply admire the team at Cannabis Amnesty for their relentless pursuit of fairness and are honored to be a part of affording others the opportunity to also be a part of this critical cause."
"People of today should not bear the burden of the laws of yesterday; while the world has changed and we are able to profit from the industry, it is our civic duty to liberate those who do not enjoy this privilege," said Drew Henson, founder and CEO of TOQi Technologies. "The hard-working and passionate advocates at Cannabis Amnesty have set the stage to right some of these wrongs, and we are honored to support their cause."
Legislative Map
Cannabis Business Times’ interactive legislative map is another tool to help cultivators quickly navigate state cannabis laws and find news relevant to their markets. View More